High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia

Blood

Volumn 103, Issue 6, 2004, Pages 2316-2324

  Harada, Hironori ^a   Harada, Yuka ^b   Niimi, Hiromasa ^b   Kyo, Taiichi ^b   Kimura, Akiro ^b   Inaba, Toshiya ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR RUNX1;

ADOLESCENT; ADULT; AGED; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA BINDING; FEMALE; GENE; GENE LOCATION; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REFRACTORY ANEMIA; RUNX1 GENE; SEQUENCE HOMOLOGY; SOMATIC MUTATION;

EID: 1542373639     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-09-3074     Document Type: Article

References (33)

1. Look AT. Oncogenic transcription factors in the human acute leukemias. Science, 1997;278:1059-1064.
2. Downing JR. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Br J Haematol. 1999;106:296-308.
3. Osato M, Asou N, Abdalla E, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2αB gene associated with myeloblastic leukemias. Blood. 1999;93:1817-1824.
4. Preudhomme C, Warot-Loze D, Roumier C, et al. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood, 2000;96:2862-2869.
5. Langabeer SE, Gale RE, Rollinson SJ, Morgan GJ, Linch DC. Mutations of the AML1 gene in acute myeloid leukemia of FAB types MO and M7. Genes Chromosomes Cancer. 2002;34:24-32.
6. Silva FP, Morolli B, Storlazzi CT, et al. Identification of RUNX1/AML1 as a classical tumor suppressor gene. Oncogene. 2003;22:538-547.
7. Harada H, Harada Y, Tanaka H, Kimura A, Inaba T. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myetodysplastic syndrome/acute leukemia, Blood. 2003;101:673-680.
8. Song W-J, Sullivan MG, Legare RD, et al. Haplo-insufficiency of CBFA2 causes familial thrombo-cytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23;166-175.
9. Buijs A, Poddighe P, van Wijk R, et al. A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. Blood. 2001;98:2856-2858.
10. Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis, Blood. 2002;99:1364-1372.
11. Bravo J, Li Z, Speck NA, Warren AJ. The leukemia-associated AML1 (Runx1)-CBFβ complex functions as a DNA-induced molecular clamp. Nat Struct Biol. 2001;8:371-378.
12. Tahirov TH, Inoue-Bungo-T, Morii H, et al. Structural analysis of DNA recognition by the AML1/Runx-1 runt domain and its allosteric control by CBFβ. Cell. 2001;104:755-767.
13. Berardi MJ, Sun C, Zehr M, et al. The Ig fold of the core binding factor alpha Runt domain is a member of a family of structurally and functionally related Ig-fold DNA-binding domains. Structure Fold Des. 1999;7:1247-1256.
14. Nagata T, Gupta V, Sorce D, et al. Immunoglobulin motif DNA recognition and heterodimerization of the PEBP2/CBF Runt domain. Nat Struct Biol. 1999;7:615-619.
15. Otto F, Kanegane H, Mundlos S. Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. Hum Mutat. 2002;19:209-216.
16. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451-458.
17. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myeiodysplastic syndromes. Br J Haematol. 1982;51:188-189.
18. Mitelman, F, ed. An International System for Human Cytogenetic Nomenclature (1995): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel, Switzerland: S Karger; 1995.
19. Tanaka Y, Fujii M, Hayashi K, et al. The chimeric protein, PEBP2 beta/ CBF beta-SMMHC, disorganizes cytoplasmic stress fibers and inhibits transcriptional activation. Oncogene. 1998;17:699-708.
20. Zhang D-E, Hetherington CJ, Meyers S, et al. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBFα2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol. 1996;16:1231-1240.
21. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 1991;19:2499.
22. Harada Y, Harada H, Downing JR, Kimura A. A hematopoietic-specific transmembrane protein, Art-1, is possibly regulated by AML1. Biochem Biophys Res Commun. 2001;284:714-722.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:659-663.
24. Imai Y, Kurokawa M, Izutsu K, et al. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood. 2000;96:3154-3160.
25. Kanno Y, Kanno T, Sakakura C, Bae SC, Ito Y. Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation. Mol Cell Biol. 1998;18:4252-4261.
26. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
27. BeghiniA, Peterlongo P, Ripamonti CB, et al. C-kit mutations in core binding factor leukemias. Blood. 2000;95:726-727.
28. Care RS, Valk PJM, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003;121:775-777.
29. Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003;3:173-183.
30. Fenaux P, Morel P, Lai JL. Cytogenetics of myelodysplastic syndrome. Semin Hematol. 1996;33:127-138.
31. Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol. 2001;73:429-437.
32. Carnicer MJ, Nomdedeu JF, Lasa A, et al. AML-1 mutations outside the RUNT domain: description of two cases in myeloid malignancies. Leukemia. 2002;16:2329-2332.
33. Tanaka T, Tanaka K, Ogawa S, et al. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. EMBO J. 1995;14:341-350.